vs
Arbutus Biopharma Corp（ABUS）与ABVC BIOPHARMA, INC.（ABVC）财务数据对比。点击上方公司名可切换其他公司
Arbutus Biopharma Corp的季度营收约是ABVC BIOPHARMA, INC.的1.3倍（$1.1M vs $796.0K）。ABVC BIOPHARMA, INC.同比增速更快（104.5% vs -33.2%）。过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs -17.2%）
Arbutus生物制药是一家公开上市的加拿大生物制药企业，专长于脂质体药物递送与RNA干扰技术，目前主要开展针对乙型肝炎感染的治疗药物研发工作，在抗病毒新药研发领域拥有深厚的技术积累。
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
ABUS vs ABVC — 直观对比
营收规模更大
ABUS
是对方的1.3倍
$796.0K
营收增速更快
ABVC
高出137.7%
-33.2%
两年增速更快
ABVC
近两年复合增速
-17.2%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $796.0K |
| 净利润 | — | $-2.0M |
| 毛利率 | — | 100.0% |
| 营业利润率 | -503.3% | -246.8% |
| 净利率 | — | -256.6% |
| 营收同比 | -33.2% | 104.5% |
| 净利润同比 | — | -417.4% |
| 每股收益（稀释后） | $-0.01 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABUSABVC
| Q4 25 | $1.1M | — | ||
| Q3 25 | $529.0K | $796.0K | ||
| Q2 25 | $10.7M | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | $1.6M | $2.0K | ||
| Q3 24 | $1.3M | $389.3K | ||
| Q2 24 | $1.7M | $117.1K | ||
| Q1 24 | $1.5M | $1.2K |
净利润ABUSABVC
| Q4 25 | — | — | ||
| Q3 25 | $-7.7M | $-2.0M | ||
| Q2 25 | $2.5M | — | ||
| Q1 25 | $-24.5M | — | ||
| Q4 24 | — | $-731.6K | ||
| Q3 24 | $-19.7M | $-394.8K | ||
| Q2 24 | $-19.8M | $-942.3K | ||
| Q1 24 | $-17.9M | $-2.8M |
毛利率ABUSABVC
| Q4 25 | — | — | ||
| Q3 25 | — | 100.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 100.0% | ||
| Q3 24 | — | 99.9% | ||
| Q2 24 | — | 99.8% | ||
| Q1 24 | — | 77.0% |
营业利润率ABUSABVC
| Q4 25 | -503.3% | — | ||
| Q3 25 | -1636.9% | -246.8% | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | -1456.9% | — | ||
| Q4 24 | -885.2% | -35837.4% | ||
| Q3 24 | -1601.2% | -77.7% | ||
| Q2 24 | -1250.5% | -734.2% | ||
| Q1 24 | -1263.9% | -235539.8% |
净利率ABUSABVC
| Q4 25 | — | — | ||
| Q3 25 | -1463.5% | -256.6% | ||
| Q2 25 | 23.5% | — | ||
| Q1 25 | -1390.4% | — | ||
| Q4 24 | — | -37211.3% | ||
| Q3 24 | -1472.5% | -101.4% | ||
| Q2 24 | -1146.9% | -804.4% | ||
| Q1 24 | -1166.8% | -235203.2% |
每股收益（稀释后）ABUSABVC
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $-0.04 | $-0.09 | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | $-0.13 | — | ||
| Q4 24 | $-0.07 | $-0.02 | ||
| Q3 24 | $-0.10 | $-0.03 | ||
| Q2 24 | $-0.11 | $-0.08 | ||
| Q1 24 | $-0.10 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $91.5M | $257.2K |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $76.6M | $12.1M |
| 总资产 | $94.6M | $21.2M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ABUSABVC
| Q4 25 | $91.5M | — | ||
| Q3 25 | $22.4M | $257.2K | ||
| Q2 25 | $37.4M | — | ||
| Q1 25 | $37.1M | — | ||
| Q4 24 | $122.6M | $313.1K | ||
| Q3 24 | $31.8M | $208.2K | ||
| Q2 24 | $62.8M | $200.0K | ||
| Q1 24 | $43.1M | $106.4K |
总债务ABUSABVC
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
股东权益ABUSABVC
| Q4 25 | $76.6M | — | ||
| Q3 25 | $77.4M | $12.1M | ||
| Q2 25 | $83.0M | — | ||
| Q1 25 | $79.2M | — | ||
| Q4 24 | $97.4M | $1.2M | ||
| Q3 24 | $106.9M | $1.6M | ||
| Q2 24 | $122.5M | $1.8M | ||
| Q1 24 | $114.6M | $1.7M |
总资产ABUSABVC
| Q4 25 | $94.6M | — | ||
| Q3 25 | $97.7M | $21.2M | ||
| Q2 25 | $103.3M | — | ||
| Q1 25 | $117.0M | — | ||
| Q4 24 | $131.7M | $7.5M | ||
| Q3 24 | $140.4M | $7.8M | ||
| Q2 24 | $160.0M | $8.0M | ||
| Q1 24 | $150.3M | $8.0M |
负债/权益比ABUSABVC
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.7M | $-964.7K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABUSABVC
| Q4 25 | $-4.7M | — | ||
| Q3 25 | $-5.8M | $-964.7K | ||
| Q2 25 | $-15.7M | — | ||
| Q1 25 | $-13.4M | — | ||
| Q4 24 | $-10.3M | $-702.1K | ||
| Q3 24 | $-20.7M | $60.2K | ||
| Q2 24 | $-14.5M | $-211.4K | ||
| Q1 24 | $-19.3M | $-955.8K |
自由现金流ABUSABVC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-10.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-19.4M | — |
自由现金流率ABUSABVC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -660.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -840.4% | — | ||
| Q1 24 | -1265.7% | — |
资本支出强度ABUSABVC
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 6.2% | — |
现金转化率ABUSABVC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
